Three-dimensional culture enhances the antimicrobial activity of mesenchymal stem cells against Shiga toxin-producing Escherichia coli O157:H7 in vitro.
Bicer M., Öztürk E., Sener F., Türkyılmaz S., Fidan Ö.
Animal Study, published in J Appl Microbiol (2026) — summary generated from the PubMed abstract.
Evidence from laboratory and animal studies provides groundwork for understanding mechanisms and potential before human studies continue.
- Level A · Stronger Clinical Evidence
- Level B · Emerging clinical evidence with positive signals
- Level C · Early human research exploring benefits
- Level D · Scientific groundwork from lab and animal studies
- Emerging · Emerging topic under active research
This page is generated from the PubMed record. The Thai description is an automated summary of bibliographic fields and the abstract, not a full translation, and is not medical advice.
- Study type
- Animal Study
- Journal
- J Appl Microbiol (2026)
- Country
- England
- Reported sample size
- —
- Source database
- PubMed
- PMID
- 42138636
- DOI
- 10.1093/jambio/lxag118
Abstract (original English)
This study examines the in vitro antibacterial activity of palatal adipose tissue-derived mesenchymal stem cells (PAT-MSCs) and the expression of antimicrobial peptide LL-37, with a particular focus on the effect of three-dimensional (3D) nanofibrillar cellulose-based hydrogel against Shiga toxin-producing Escherichia coli (STEC) harboring stx1 and/or stx2 genes isolated from mastitis milk in Turkey. The antibacterial activity of conventionally cultured PAT-MSCs and 3D-cultured PAT-MSCs (PAT-MSCs-3D) was evaluated against STEC isolates and Escherichia coli ATCC 35150 using quantitative colony-forming unit (CFU) assay. The expression levels of antimicrobial peptide (AMP)-encoding genes were evaluated by quantitative real-time PCR, and AMP production was further validated by immunocytochemical staining. The results indicated that PAT-MSCs-3D exhibited significantly enhanced antibacterial efficacy, resulting in marked bacterial inhibition of all tested STEC strains, with bacterial reductions reaching up to 6-7 log under specific experimental conditions. Molecular and immunocytochemical analyses demonstrated increased expression of the antimicrobial peptide LL-37 in PAT-MSCs-3D compared to 2D cultures. Our results show that culturing PAT-MSCs in 3D conditions leads to a significant enhancement in their antimicrobial properties, which could be linked to the upregulation of LL-37.
What this study does not prove
- • This study does not prove SVF is an approved treatment or a replacement for standard care.
- • This is preclinical work; animal or laboratory results cannot be applied to humans.
Evidence level
Evidence from laboratory and animal studies provides groundwork for understanding mechanisms and potential before human studies continue.
How we grade evidenceBrowse all related research
Filter the research library by this study's title keywords, author, or publication year.